Loading...
Market
What will be the outcome of PBGENE-HBV trial's primary endpoint by end of 2025?
2
Resolution / Starting Odds
Met primary endpoint • 25%
Partially met primary endpoint • 25%
Did not meet primary endpoint • 25%
Trial inconclusive • 25%
Published results in medical journals or official press releases from Precision BioSciences
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
FDA approval granted • 25%
FDA approval denied • 25%
Further trials required • 25%
Withdrawn by Gilead • 25%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Significant reduction in HIV levels (over 1000-fold) • 25%
Moderate reduction in HIV levels (100-1000 fold) • 25%
Minimal reduction in HIV levels (less than 100 fold) • 25%
No significant reduction in HIV levels • 25%
Approved • 25%
Rejected • 25%
Request for more data • 25%
Other • 25%
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Study inconclusive • 25%
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%